Ann: Key OmniCAR Patent Granted in US, page-19

Hi Big Dan, I try not to get carried away with even quietly contemplating where the MCap or SP could be years from now. However, I do question why the hell our MCap and SP is where it is when the company has barely put a foot wrong and has built what has to be considered a foolproof portfolio of impressive techonology and a team of impressive experts. Not only that, we now have two platforms with monetizeable products. There are few biotech companies on the ASX with that sort of arsenal. PTX still seems under the radar, Dan... but it's starting to get that feel about it that perhaps our exposure is about to change.

I've not been a holder for all that long but, in reading back through PTX's history and trial data, its seems to me that none of PTX's moves and tech have failed in any way whatsoever. Our targeted therapies PTX100 and 200 have been turning out successful data - both great percentage of efficacy, both excellent levels of safety, both with orphan drug designation and both aimed at truncated registrational trials. EIther or both have the potential to be taken through to commercialisation as a monotherapy or be partnered up (due to low to zero toxicity) as a combo treatments. Our OmniCAR platform has even exceeded expectations with its pre-clinical data, so the future is bright there. Our CarT therapies thus far are looking great with entry into clinical trials in combo with OmniCAR is super exciting. And, we now have our own superior Cell Therapy Enhancement programs that have just unveiled the first of yet another monetisable product of a new platform to catapult PTX into the spotlight.

I'm with you, I reckon PTX is pretty special too. The boxes are all getting ticked. The only hiccups that we have encountered in the last year are those that temporarily derailed the timelines of our two clinical trials. Both were waylaid due to CoVid-related disruptions to manufacturing runs, which were out of our control. And, of course, the global shit-show has not helped the sector or the SP one-iota. But what they have induced, is an opportunity to buy PTX at a far reduced price, with all the newsflow ahead of us. I would love to see PTX get far greater mainstream attention.